Serum Isthmin-1 and Meteorin-like Protein in Newly Diagnosed, Drug-Naïve Type 2 Diabetes with and Without Fatty Liver Index–Defined Hepatic Steatosis: A Cross-Sectional Study
Keywords:
isthmin-1, meteorin-like protein, type 2 diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, fatty liver index, insulin resistanceAbstract
Background: Isthmin-1 (ISM1) and meteorin-like protein (Metrnl) regulate glucose and lipid metabolism, but human data in type 2 diabetes mellitus (T2DM) with metabolic dysfunction-associated steatotic liver disease are scarce and conflicting. We compared both proteins in drug-naïve T2DM according to hepatic steatosis status.
Methods: This cross-sectional study at Al-Yarmouk Teaching Hospital, Baghdad, analyzed 84 drug-naïve patients with newly diagnosed T2DM and 33 non-diabetic controls. Patients were classified by fatty liver index (FLI) as FLI < 60 (n = 26) or FLI ≥ 60 (steatosis; n = 58). Serum ISM1 and Metrnl were measured by ELISA and evaluated by logistic regression and receiver operating characteristic analysis.
Results: ISM1 decreased stepwise from controls (4.01 ± 0.66 ng/mL) to patients with FLI < 60 (3.43 ± 0.60) and FLI ≥ 60 (2.56 ± 0.65; all pairwise p ≤ 0.002). Metrnl was higher in patients with FLI < 60 than in controls (median 426.7 vs 346.1 pg/mL; p = 0.005) but lowest with FLI ≥ 60 (283.8 pg/mL; p < 0.001). After adjustment for age, sex and HOMA-IR, the odds ratios for steatosis per 1-SD increase were 0.32 (0.13–0.74) for ISM1 and 0.36 (0.15–0.83) for Metrnl. Areas under the curve were 0.827 (ISM1), 0.881 (Metrnl) and 0.898 (combined; optimism-corrected 0.891); the combination did not significantly outperform Metrnl alone (p = 0.421).
Conclusions: In drug-naïve T2DM, lower serum ISM1 and Metrnl were independently associated with FLI-defined steatosis, and Metrnl deviated in opposite directions depending on steatosis status. These hypothesis-generating findings require confirmation with imaging-based steatosis assessment in independent cohorts.